Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
Windtree Therapeutics to Present at Lytham Partners Conference
Windtree Therapeutics, Inc. (NASDAQ: WINT) announced that its CEO Craig Fraser will present at the Lytham Partners Spring 2022 Investor Conference on April 4, 2022, at 11:00 AM. The conference will be held virtually from April 4-7, 2022. Interested parties can click HERE for the live webcast. The company focuses on developing late-stage interventions for acute cardiovascular and pulmonary disorders, including its lead candidate, istaroxime, for acute heart failure.
- None.
- None.
Company to present on Monday, April 4, 2022 at 11:00 am
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022. Details are as follows:
| Lytham Partners Spring 2022 Investor Conference | |
| Presentation: | Monday, April 4, 2022 |
| Time: | 11:00 am |
| Link: | Click HERE |
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.
A live webcast and replay of the presentation will be available on the Investor Page of the company’s website (www.windtreetx.com).
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the clinical development of AEROSURF®, to its licensee in Asia, Lee's HK. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com
Media contact:
Andrew Mielach
LifeSci Communications
646.876.5868 or amielach@lifescicomms.com
FAQ
When will Windtree Therapeutics present at the Lytham Partners conference?
What is the focus of Windtree Therapeutics?
Where can I watch the Windtree Therapeutics presentation?
Who will represent Windtree Therapeutics at the conference?
